Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Controlled High-risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurologic Surveillance (CHAMPIONS10)
Brief Summary: The current study is a continuation of the 5 year extension study of the phase III CHAMPS study (see reference). This study was designed to determine if immediate initiation of therapy with Interferon Beta-1a (AVONEX) after a first attack of multiple sclerosis (MS) continues to delay the development of further attacks (CDMS) and the development of neurological disability over a 10 year period of observation. The initial 5 year extension study, called CHAMPIONS5, reported that immediate initiation of interferon Beta-1a (AVONEX) after a first attack of MS continued to delay the development of CDMS and lowered relapse rates compared to delayed initiation of disease modifying treatment (usually with AVONEX) either at the time of a second attack or at the end of the phase III study (24 months). The study was extended to 10 years to determine if these effects are sustained and result in less long term permanent disability.


Options:
A: Arm Label: Immediate Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: interferon beta 1a 30 ug IM once weekly | Arm Label: Delayed Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon beta 1a 30 ug IM once weekly | Intervention Type: DRUG; Name: interferon beta 1a 30 ug IM once weekly; Assigned to Arm(s): Delayed Treatment Group, Immediate Treatment Group
B: Arm Label: RNF 44 mcg three times weekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF | Arm Label: RNF 44 mcg once weekly and placebo twice weekly for blinding; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF, Drug: Placebo | Arm Label: Placebo three times weekly; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo twice weekly for blinding, RNF 44 mcg three times weekly | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo twice weekly for blinding, RNF 44 mcg three times weekly | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo three times weekly, RNF 44 mcg once weekly and placebo twice weekly for blinding
C: Arm Label: RNF 44 mcg thrice weekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF | Arm Label: RNF 44 mcg once weekly and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF, Drug: Placebo | Arm Label: Placebo/RNF 44 mcg thrice weekly; Type: ACTIVE_COMPARATOR; Interventions: Drug: RNF | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg thrice weekly | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): RNF 44 mcg once weekly and placebo | Intervention Type: DRUG; Name: RNF; Assigned to Arm(s): Placebo/RNF 44 mcg thrice weekly | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): RNF 44 mcg once weekly and placebo
D: Arm Label: Initial IFNB-1b (Interferon beta-1b); Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Arm Label: Initial Placebo; Type: EXPERIMENTAL; Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): Initial IFNB-1b (Interferon beta-1b) | Intervention Type: DRUG; Name: Interferon beta-1b (Betaseron, BAY86-5046); Assigned to Arm(s): Initial Placebo

Answer: A